跳至主要内容
临床试验/IRCT2014122720441N1
IRCT2014122720441N1已完成未知

Effect of omega 3 on inflammatory marker, hs-CRP, and 30-days major adverse cardiac effects (MACE) after percutaneous coronary intervention (PCI) in chronic kidney disease patients (CKD)

Shiraz University of Medical Sciences, International branch0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • Informed consent form; NSTE-ACS candidate for elective PCI; treatment with ASA at least 5 days before PCI; CKD patients (GFR ? 60 ml/min) Exclusion criteria: CABG during last 3 months; treatment with glycoprotein IIb/IIIa inhibitors during PCI; treatment with bivalirudine during PCI; sensitivity or tolerance to ASA or Clopidogrel; unsatisfactory PCI; sever active bleeding; sever adverse effects to drugs

排除标准

  • 未提供

研究者

发起方
Shiraz University of Medical Sciences, International branch

相似试验